Latest filings (excl ownership)
6-K
Corporate Governance Statement
1 Oct 24
6-K
Current report (foreign)
1 Oct 24
20-F
2024 FY
Annual report (foreign)
30 Sep 24
6-K
ASX Market Announcement
11 Sep 24
6-K
Genetic Technologies receives Nasdaq notice of noncompliance with the $1 minimum bid price requirement
28 Aug 24
6-K
Global launch of geneType™ on wholly owned EasyDNA platform
15 Aug 24
6-K
Appendix 4C & Quarterly Business Update – June 2024
31 Jul 24
6-K
Strategic restructure to focus on USA sales growth
26 Jul 24
6-K
Current report (foreign)
28 Jun 24
6-K
Current report (foreign)
28 Jun 24
6-K
ASX Market Announcement
21 Jun 24
6-K
ASX Market Announcement
5 Jun 24
6-K
GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
29 May 24
EFFECT
Notice of effectiveness
28 May 24
6-K
Current report (foreign)
6 May 24
6-K
ASX Market Announcement
30 Apr 24
6-K
Current report (foreign)
23 Apr 24
6-K
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
23 Apr 24
6-K
Company Announcements Office
23 Apr 24
6-K
Current report (foreign)
23 Apr 24
6-K
Genetic Technologies Announces $2 Million Registered Direct Offering
22 Apr 24
424B5
Prospectus supplement for primary offering
22 Apr 24
6-K
Genetic Technologies Announces US$2 Million Registered Direct Offering
19 Apr 24
6-K
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
17 Apr 24
6-K
Current report (foreign)
11 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
GTG Secures Short Term Loan Facility with Radium Capital
26 Mar 24
6-K
Current report (foreign)
25 Mar 24
6-K
GTG to develop Worlds Most Advanced Comprehensive Risk Test
22 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Current report (foreign)
7 Mar 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
20 Feb 24
6-K
Current report (foreign)
15 Feb 24
6-K
Current report (foreign)
7 Feb 24
6-K
Appendix 4C & Quarterly Business Update – December 2023
31 Jan 24
6-K
Current report (foreign)
9 Jan 24
6-K
Current report (foreign)
5 Jan 24
EFFECT
Notice of effectiveness
5 Jan 24
CORRESP
Correspondence with SEC
2 Jan 24
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G
CVI Investments, Inc.
13 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
4 Jun 20
SC 13G
INTRACOASTAL CAPITAL, LLC
28 Apr 20
SC 13G/A
Genetic Technologies LTD
13 Feb 19
SC 13G
Genetic Technologies LTD
14 Feb 18
SC 13G/A
Genetic Technologies LTD
9 Feb 18
SC 13G/A
Genetic Technologies LTD
8 Jan 18
SC 13G/A
Genetic Technologies LTD
14 Feb 17
SC 13G/A
Genetic Technologies LTD
10 Feb 17
SC 13G/A
Genetic Technologies LTD
12 Jan 17
SC 13G
Genetic Technologies LTD
14 Dec 16
SC 13G
Genetic Technologies LTD
14 Dec 16
SC 13G
Genetic Technologies LTD
9 Dec 16
SC 13G/A
Genetic Technologies LTD
12 Feb 16
SC 13G/A
Genetic Technologies LTD
8 Feb 16
SC 13G/A
Genetic Technologies LTD
12 Jan 16
SC 13G
Genetic Technologies LTD
16 Mar 15
SC 13G
Genetic Technologies LTD
13 Mar 15
SC 13G
Genetic Technologies LTD
12 Mar 15
SC 13G/A
Genetic Technologies LTD
12 Feb 15
SC 13G
Genetic Technologies LTD
7 Jan 14